Century Therapeutics (IPSC) News Today → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free IPSC Stock Alerts $3.09 -0.06 (-1.90%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 5:37 PM | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Decline in Short InterestCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 1,560,000 shares, a drop of 9.8% from the April 15th total of 1,730,000 shares. Approximately 5.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 194,700 shares, the short-interest ratio is currently 8.0 days.May 14 at 2:08 AM | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) Price Target Lowered to $11.00 at HC WainwrightMay 13 at 4:50 AM | americanbankingnews.comHC Wainwright Comments on Century Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:IPSC)May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics Amid Promising Trials and Strategic AcquisitionsMay 10, 2024 | finance.yahoo.comCentury Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...May 10, 2024 | finance.yahoo.comCentury Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual MeetingMay 10, 2024 | marketbeat.comHC Wainwright Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $11.00HC Wainwright dropped their target price on shares of Century Therapeutics from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Friday.May 9, 2024 | investorplace.comIPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comCentury Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 8, 2024 | insidertrades.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Insider Sells $15,600.00 in StockMay 7, 2024 | marketbeat.comInsider Selling: Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Sells 5,000 Shares of StockCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Gregory Russotti sold 5,000 shares of Century Therapeutics stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $3.12, for a total value of $15,600.00. Following the sale, the insider now owns 292,319 shares of the company's stock, valued at approximately $912,035.28. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.April 26, 2024 | investing.comCentury Therapeutics executive sells shares worth over $15kApril 25, 2024 | insidertrades.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Insider Sells $15,500.00 in StockApril 23, 2024 | marketbeat.comTrading was temporarily halted for "IPSC" at 09:04 AM with a stated reason of "LULD pause."April 23, 2024 | finance.yahoo.comCentury Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 23, 2024 | globenewswire.comCentury Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics Amidst Strong Financial Backing and Promising Clinical AdvancesApril 14, 2024 | uk.investing.comCentury Therapeutics shares target cut, retains OverweightApril 12, 2024 | msn.comCentury Therapeutics Gears Up to Conquer Highly Unmet Areas in Autoimmune Disease TreatmentsApril 12, 2024 | marketbeat.comCentury Therapeutics' (IPSC) "Overweight" Rating Reaffirmed at Piper SandlerPiper Sandler reiterated an "overweight" rating and issued a $9.00 target price (down previously from $10.00) on shares of Century Therapeutics in a report on Friday.April 12, 2024 | markets.businessinsider.comCentury Therapeutics: Hold Rating Justified Amid Strategic Acquisition and Ongoing Clinical TrialsApril 11, 2024 | globenewswire.comCentury Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsApril 8, 2024 | globenewswire.comCentury Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 1, 2024 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Short Interest UpdateCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,640,000 shares, a decline of 6.3% from the February 29th total of 1,750,000 shares. Based on an average daily trading volume, of 214,300 shares, the short-interest ratio is presently 7.7 days. Approximately 7.6% of the company's shares are sold short.March 29, 2024 | finance.yahoo.comCentury Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash WiselyMarch 19, 2024 | markets.businessinsider.comStrong Buy Rating for Century Therapeutics Amid Promising CNTY-101 Developments and Market CatalystsMarch 19, 2024 | globenewswire.comCentury Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 18, 2024 | marketbeat.comCanaccord Genuity Group Increases Century Therapeutics (NASDAQ:IPSC) Price Target to $24.00Canaccord Genuity Group lifted their price objective on Century Therapeutics from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday.March 18, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $13.00 price target on shares of Century Therapeutics in a report on Friday.March 18, 2024 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have giveMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics on Strong Clinical and Financial OutlookMarch 15, 2024 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 14, 2024 | investorplace.comIPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023March 14, 2024 | benzinga.comCentury Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comCentury Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 11, 2024 | msn.comCentury Therapeutics to Showcase Groundbreaking Cancer Research at AACR Annual Meeting 2024March 11, 2024 | insidertrades.comAdrienne Farid Sells 22,831 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) StockMarch 9, 2024 | finance.yahoo.comCentury Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 SharesMarch 8, 2024 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Insider Adrienne Farid Sells 22,831 SharesCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Adrienne Farid sold 22,831 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $5.14, for a total transaction of $117,351.34. Following the transaction, the insider now directly owns 114,149 shares in the company, valued at approximately $586,725.86. The transaction was disclosed in a filing with the SEC, which is available through this link.March 8, 2024 | marketbeat.comFmr LLC Cuts Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC)Fmr LLC trimmed its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 12.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,524,629 shares of the company's stock after selling 643,March 5, 2024 | globenewswire.comCentury Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingFebruary 22, 2024 | investorplace.com3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024February 16, 2024 | marketbeat.comShort Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 6.4%Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 846,300 shares, a growth of 6.4% from the January 15th total of 795,600 shares. Currently, 3.7% of the company's shares are sold short. Based on an average daily volume of 183,100 shares, the days-to-cover ratio is currently 4.6 days.February 15, 2024 | seekingalpha.comIPSC Century Therapeutics, Inc.February 14, 2024 | investing.comCentury Therapeutics Inc (IPSC)February 1, 2024 | finance.yahoo.comCentury Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 22, 2024 | benzinga.comIN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising DataDecember 13, 2023 | markets.businessinsider.comHold Rating on Century Therapeutics Amid Early Clinical Data and Market SpeculationDecember 9, 2023 | finance.yahoo.comCentury Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ EditsDecember 8, 2023 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics: Promising Clinical Data and Financial Stability Highlight Potential Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman. Get the full story here. IPSC Media Mentions By Week IPSC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPSC News Sentiment▼0.830.54▲Average Medical News Sentiment IPSC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPSC Articles This Week▼162▲IPSC Articles Average Week Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADVM News IPHA News KOD News CMPX News INMB News ABOS News ZURA News MGX News OPT News AGEN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPSC) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
